Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248

@article{Potapova2006ContributionOI,
  title={Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248},
  author={O. Potapova and A. Laird and M. Nannini and A. Barone and Guangmin Li and K. Moss and J. Cherrington and D. Mendel},
  journal={Molecular Cancer Therapeutics},
  year={2006},
  volume={5},
  pages={1280 - 1289}
}
Recent achievements in the development of multitargeted molecular inhibitors necessitate a better understanding of the contribution of activity against individual targets to their efficacy. SU11248, a small-molecule inhibitor targeting class III/V receptor tyrosine kinases, including the platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) receptors, KIT and FLT3, exhibits direct effects on cancer cells as well as antiangiogenic activity. Here, we investigated the… Expand
110 Citations
SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity
  • 90
  • PDF
Novel targets for VEGF-independent anti-angiogenic drugs
  • 33
Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies.
  • 129
Soluble receptor-mediated selective inhibition of VEGFR and PDGFRβ signaling during physiologic and tumor angiogenesis
  • 91
  • Highly Influenced
  • PDF
A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities.
  • J. Christensen
  • Medicine
  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2007
  • 107
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 42 REFERENCES
SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
  • 485
  • PDF
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.
  • 1,338
  • PDF
Therapies directed at vascular endothelial growth factor
  • 100
Pharmacology of imatinib (STI571).
  • 243
SU6668 inhibits Flk‐1/KDR and PDGFRβ in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice
  • 150
Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents
  • 132
...
1
2
3
4
5
...